메뉴 건너뛰기




Volumn 60, Issue 1, 2014, Pages 55-70

Optimal treatment of hepatic encephalopathy

Author keywords

Hepatic encephalopathy; Lactulose; Rifaximin; Therapeutics

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ACARBOSE; AMMONIA; BENZOIC ACID; BRANCHED CHAIN AMINO ACID; FLUMAZENIL; INTERLEUKIN 1; INTERLEUKIN 6; LACTITOL; LACTULOSE; METRONIDAZOLE; N METHYL DEXTRO ASPARTIC ACID; NEOMYCIN; ORNITHINE ASPARTATE; PLACEBO; PROBIOTIC AGENT; RIFAXIMIN; TUMOR NECROSIS FACTOR ALPHA; VANCOMYCIN; ZINC;

EID: 84899676816     PISSN: 1121421X     EISSN: 18271642     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (10)

References (96)
  • 1
    • 0036191173 scopus 로고    scopus 로고
    • Hepatic encephalopathy - Definition, nomenclature, diagnosis, and quantification: Final report of the Working Party at the 11th World Congresses of Gastroenterology, Vienna, 1998
    • DOI 10.1053/jhep.2002.31250
    • Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002;35:716-21. (Pubitemid 34183979)
    • (2002) Hepatology , vol.35 , Issue.3 , pp. 716-721
    • Ferenci, P.1    Lockwood, A.2    Mullen, K.3    Tarter, R.4    Weissenborn, K.5    Blei, A.T.6
  • 2
    • 44949122693 scopus 로고    scopus 로고
    • Hepatic Encephalopathy
    • DOI 10.1016/j.mcna.2008.03.009, PII S0025712508000266
    • Munoz SJ. Hepatic encephalopathy. Med Clin North Am 2008;92:795-812, viii. (Pubitemid 351822357)
    • (2008) Medical Clinics of North America , vol.92 , Issue.4 , pp. 795-812
    • Munoz, S.J.1
  • 3
    • 33846446011 scopus 로고    scopus 로고
    • Review article: The burden of hepatic encephalopathy
    • DOI 10.1111/j.1746-6342.2006.03215.x
    • Poordad FF. Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther 2007;25(Suppl 1):3-9. (Pubitemid 46148239)
    • (2007) Alimentary Pharmacology and Therapeutics , vol.25 , Issue.SUPPL. 1 , pp. 3-9
    • Poordad, F.F.1
  • 5
    • 34548136516 scopus 로고    scopus 로고
    • Minimal hepatic encephalopathy: A vehicle for accidents and traffic violations
    • DOI 10.1111/j.1572-0241.2007.01424.x
    • Bajaj JS, Hafeezullah M, Hoffmann RG, Saeian K. Minimal hepatic encephalopathy: a vehicle for accidents and traffic violations. Am J Gastroenterol 2007;102:1903-9. (Pubitemid 47301540)
    • (2007) American Journal of Gastroenterology , vol.102 , Issue.9 , pp. 1903-1909
    • Bajaj, J.S.1    Hafeezullah, M.2    Hoffmann, R.G.3    Saeian, K.4
  • 6
    • 39549107131 scopus 로고    scopus 로고
    • Navigation skill impairment: Another dimension of the driving difficulties in minimal hepatic encephalopathy
    • DOI 10.1002/hep.22032
    • Bajaj JS, Hafeezullah M, Hoffmann RG, Varma RR, Franco J, Binion DG et al. Navigation skill impairment: Another dimension of the driving difficulties in minimal hepatic encephalopathy. Hepatology 2008;47:596-604. (Pubitemid 351280728)
    • (2008) Hepatology , vol.47 , Issue.2 , pp. 596-604
    • Bajaj, J.S.1    Hafeezullah, M.2    Hoffmann, R.G.3    Varma, R.R.4    Franco, J.5    Binion, D.G.6    Hammeke, T.A.7    Saeian, K.8
  • 9
    • 70350075400 scopus 로고    scopus 로고
    • Minimal hepatic encephalopathy is associated with motor vehicle crashes: The reality beyond the driving test
    • Bajaj JS, Saeian K, Schubert CM, Hafeezullah M, Franco J, Varma RR et al. Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology 2009;50:1175-83.
    • (2009) Hepatology , vol.50 , pp. 1175-1183
    • Bajaj, J.S.1    Saeian, K.2    Schubert, C.M.3    Hafeezullah, M.4    Franco, J.5    Varma, R.R.6
  • 12
    • 20044372736 scopus 로고    scopus 로고
    • AASLD practice guidelines: Evaluation of the patient for liver transplantation
    • DOI 10.1002/hep.20704
    • Murray KF, Carithers RL, Jr., Aasld. AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology 2005;41:1407-32. (Pubitemid 40770295)
    • (2005) Hepatology , vol.41 , Issue.6 , pp. 1407-1432
    • Murray, K.F.1    Carithers Jr., R.L.2
  • 13
    • 84865320804 scopus 로고    scopus 로고
    • In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009
    • Stepanova M, Mishra A, Venkatesan C, Younossi ZM. In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009. Clin Gastroenterol Hepatol 2012;10:1034-41 e1.
    • (2012) Clin Gastroenterol Hepatol , vol.10
    • Stepanova, M.1    Mishra, A.2    Venkatesan, C.3    Younossi, Z.M.4
  • 14
    • 33847213560 scopus 로고    scopus 로고
    • Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy
    • Leevy CB, Phillips JA. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci 2007;52:737-41.
    • (2007) Dig Dis Sci , vol.52 , pp. 737-741
    • Leevy, C.B.1    Phillips, J.A.2
  • 16
    • 34548174883 scopus 로고    scopus 로고
    • Clinical manifestation, and Diagnosis of Hepatic Encephalopathy
    • D MK. Pathogenesis, Clinical manifestation, and Diagnosis of Hepatic Encephalopathy. Semin Liver Dis 2007:3-9.
    • (2007) Semin Liver Dis , pp. 3-9
    • Pathogenesis, D.M.K.1
  • 17
    • 0023277382 scopus 로고
    • Biochemistry and physiology of brain ammonia
    • Cooper AJ, Plum F. Biochemistry and physiology of brain ammonia. Physiol Rev 1987;67:440-519. (Pubitemid 17063608)
    • (1987) Physiological Reviews , vol.67 , Issue.2 , pp. 440-519
    • Cooper, A.J.L.1    Plum, F.2
  • 18
    • 0343238857 scopus 로고    scopus 로고
    • Hepatic encephalopathy in chronic liver disease: A clinical manifestation of astrocyte swelling and low-grade cerebral edema?
    • DOI 10.1016/S0168-8278(00)80110-5
    • Haussinger D, Kircheis G, Fischer R, Schliess F, vom Dahl S. Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema? J Hepatol 2000;32:1035-8. (Pubitemid 30368099)
    • (2000) Journal of Hepatology , vol.32 , Issue.6 , pp. 1035-1038
    • Haussinger, D.1    Kircheis, G.2    Fischer, R.3    Schliess, F.4    Dahl, S.V.5
  • 19
    • 0025979046 scopus 로고
    • Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy
    • Lockwood AH, Yap EW, Wong WH. Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J Cereb Blood Flow Metab 1991;11:337-41.
    • (1991) J Cereb Blood Flow Metab , vol.11 , pp. 337-341
    • Lockwood, A.H.1    Yap, E.W.2    Wong, W.H.3
  • 20
    • 33745548101 scopus 로고    scopus 로고
    • Low grade cerebral edema and the pathogenesis of hepatic encephalopathy in cirrhosis
    • DOI 10.1002/hep.21235
    • Haussinger D. Low grade cerebral edema and the pathogenesis of hepatic encephalopathy in cirrhosis. Hepatology 2006;43:1187-90. (Pubitemid 43980095)
    • (2006) Hepatology , vol.43 , Issue.6 , pp. 1187-1190
    • Haussinger, D.1
  • 21
  • 22
    • 0025292201 scopus 로고
    • "Endogenous" benzodiazepine activity in body fluids of patients with hepatic encephalopathy
    • 14
    • Mullen KD, Szauter KM, Kaminsky-Russ K. "Endogenous" benzodiazepine activity in body fluids of patients with hepatic encephalopathy. Lancet 1990 14;336(8707):81-3.
    • (1990) Lancet , vol.336 , Issue.8707 , pp. 81-83
    • Mullen, K.D.1    Szauter, K.M.2    Kaminsky-Russ, K.3
  • 24
    • 77957345947 scopus 로고    scopus 로고
    • Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy
    • Gupta A, Dhiman RK, Kumari S, Rana S, Agarwal R, Duseja A et al. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. J Hepatol 2010;53:849-55.
    • (2010) J Hepatol , vol.53 , pp. 849-855
    • Gupta, A.1    Dhiman, R.K.2    Kumari, S.3    Rana, S.4    Agarwal, R.5    Duseja, A.6
  • 25
    • 77953638458 scopus 로고    scopus 로고
    • Association between small intestinal bacterial overgrowth and peripheral bacterial DNA in cirrhotic patients
    • Jun DW, Kim KT, Lee OY, Chae JD, Son BK, Kim SH et al. Association between small intestinal bacterial overgrowth and peripheral bacterial DNA in cirrhotic patients. Dig Dis Sci 2010;55:1465-71.
    • (2010) Dig Dis Sci , vol.55 , pp. 1465-1471
    • Jun, D.W.1    Kim, K.T.2    Lee, O.Y.3    Chae, J.D.4    Son, B.K.5    Kim, S.H.6
  • 26
    • 84856407574 scopus 로고    scopus 로고
    • Rifaximin reduces endotoxemia and improves liver function and disease severity in patients withompensated cirrhosis
    • Kalambokis GN, Tsianos EV. Rifaximin reduces endotoxemia and improves liver function and disease severity in patients withompensated cirrhosis. Hepatology 2012;55:655-6.
    • (2012) Hepatology , vol.55 , pp. 655-656
    • Kalambokis, G.N.1    Tsianos, E.V.2
  • 28
    • 84875670330 scopus 로고    scopus 로고
    • Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy
    • Bajaj JS, Heuman DM, Sanyal AJ, Hylemon PB, Sterling RK, Stravitz RT et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One 2013;8:e60042.
    • (2013) PLoS One , vol.8
    • Bajaj, J.S.1    Heuman, D.M.2    Sanyal, A.J.3    Hylemon, P.B.4    Sterling, R.K.5    Stravitz, R.T.6
  • 29
    • 84866396844 scopus 로고    scopus 로고
    • Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation
    • Bajaj JS, Hylemon PB, Ridlon JM, Heuman DM, Daita K, White MB et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol 2012;303:G675-85.
    • (2012) Am J Physiol Gastrointest Liver Physiol , vol.303
    • Bajaj, J.S.1    Hylemon, P.B.2    Ridlon, J.M.3    Heuman, D.M.4    Daita, K.5    White, M.B.6
  • 30
    • 79953765823 scopus 로고    scopus 로고
    • Hepatic encephalopathy: A central neuroinflammatory disorder?
    • Butterworth RF. Hepatic encephalopathy: a central neuroinflammatory disorder? Hepatology 2011;53:1372-6.
    • (2011) Hepatology , vol.53 , pp. 1372-1376
    • Butterworth, R.F.1
  • 31
    • 79960714764 scopus 로고    scopus 로고
    • Characterization of fecal microbial communities in patients with liver cirrhosis
    • Chen Y, Yang F, Lu H, Wang B, Chen Y, Lei D et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology 2011;54:562-72.
    • (2011) Hepatology , vol.54 , pp. 562-572
    • Chen, Y.1    Yang, F.2    Lu, H.3    Wang, B.4    Chen, Y.5    Lei, D.6
  • 32
    • 84884357277 scopus 로고    scopus 로고
    • Overt hepatic encephalopathy in cirrhosis: Influence of multiple clinical precipitants resulting in hospitalization
    • abstract
    • Pantham G, Waghray N, Prakash R, Biyyani RS, Mullen KD. Overt hepatic encephalopathy in cirrhosis: influence of multiple clinical precipitants resulting in hospitalization. Gastroenterology 2012;142(Suppl 1):S950 (abstract).
    • (2012) Gastroenterology , vol.142 , Issue.SUPPL. 1
    • Pantham, G.1    Waghray, N.2    Prakash, R.3    Biyyani, R.S.4    Mullen, K.D.5
  • 33
    • 79955753653 scopus 로고    scopus 로고
    • Current concepts in the pathophysiology and management of hepatic encephalopathy
    • N Y
    • Frederick RT. Current concepts in the pathophysiology and management of hepatic encephalopathy. Gastroenterol Hepatol (N Y) 2011;7:222-33.
    • (2011) Gastroenterol Hepatol , vol.7 , pp. 222-233
    • Frederick, R.T.1
  • 34
    • 14644389447 scopus 로고    scopus 로고
    • Endoscopic coagulation therapy is successful for improving encephalopathy in cirrhotic patients with gastric antral vascular ectasia
    • Zushi S IY, Fukuda K et al. Endoscopic coagulation therapy is successful for improving encephalopathy in cirrhotic patients with gastric antral vascular ectasia. Digestive Endoscopy 2005;32-5.
    • (2005) Digestive Endoscopy , pp. 32-35
    • Zushi, S.I.Y.1    Fukuda, K.2
  • 35
    • 0034944406 scopus 로고    scopus 로고
    • Practice Parameters Committee of the American College of G. Hepatic Encephalopathy
    • Blei AT, Cordoba J, Practice Parameters Committee of the American College of G. Hepatic Encephalopathy. Am J Gastroenterol 2001;96:1968-76.
    • (2001) Am J Gastroenterol , vol.96 , pp. 1968-1976
    • Blei, A.T.1    Cordoba, J.2
  • 36
    • 34548185116 scopus 로고    scopus 로고
    • An algorithm for the management of hepatic encephalopathy
    • Prakash RK, Kanna S, Mullen KD. An algorithm for the management of hepatic encephalopathy. Semin Liver Dis 2007;27(Suppl 2):32-48.
    • (2007) Semin Liver Dis , vol.27 , Issue.SUPPL. 2 , pp. 32-48
    • Prakash, R.K.1    Kanna, S.2    Mullen, K.D.3
  • 37
    • 33947387582 scopus 로고    scopus 로고
    • Can we ignore minimal hepatic encephalopathy any longer?
    • DOI 10.1002/hep.21617
    • Qadri AM, Ogunwale BO, Mullen KD. Can we ignore minimal hepatic encephalopathy any longer? Hepatology 2007;45:547-8. (Pubitemid 46450606)
    • (2007) Hepatology , vol.45 , Issue.3 , pp. 547-548
    • Qadri, A.M.1    Ogunwale, B.O.2    Mullen, K.D.3
  • 38
    • 77950586321 scopus 로고    scopus 로고
    • Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients
    • Bajaj JS, Sanyal AJ, Bell D, Gilles H, Heuman DM. Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients. Aliment Pharmacol Ther 2010;31:1012-7.
    • (2010) Aliment Pharmacol Ther , vol.31 , pp. 1012-1017
    • Bajaj, J.S.1    Sanyal, A.J.2    Bell, D.3    Gilles, H.4    Heuman, D.M.5
  • 40
    • 69249166158 scopus 로고    scopus 로고
    • Secondary prophylaxis of hepatic encephalopathy: An open-label randomized controlled trial of lactulose versus placebo
    • Sharma BC, Sharma P, Agrawal A, Sarin SK. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology 2009;137:885-91, 91 e1.
    • (2009) Gastroenterology , vol.137
    • Sharma, B.C.1    Sharma, P.2    Agrawal, A.3    Sarin, S.K.4
  • 41
    • 84864296945 scopus 로고    scopus 로고
    • Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: An open labeled randomized controlled trial of lactulose versus no lactulose
    • Sharma P, Sharma BC, Agrawal A, Sarin SK. Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose. J Gastroenterol Hepatol 2012;27:1329-35.
    • (2012) J Gastroenterol Hepatol , vol.27 , pp. 1329-1335
    • Sharma, P.1    Sharma, B.C.2    Agrawal, A.3    Sarin, S.K.4
  • 42
    • 43449114798 scopus 로고    scopus 로고
    • An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy
    • DOI 10.1097/MEG.0b013e3282f3e6f5, PII 0004273720080600000007
    • Sharma P, Sharma BC, Puri V, Sarin SK. An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol 2008;20:506-11. (Pubitemid 351667890)
    • (2008) European Journal of Gastroenterology and Hepatology , vol.20 , Issue.6 , pp. 506-511
    • Sharma, P.1    Sharma, B.C.2    Puri, V.3    Sarin, S.K.4
  • 43
    • 84863722812 scopus 로고    scopus 로고
    • Secondary prophylaxis of hepatic encephalopathy in cirrhosis: An open-label, randomized controlled trial of lactulose, probiotics, and no therapy
    • Agrawal A, Sharma BC, Sharma P, Sarin SK. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Am J Gastroenterol 2012;107:1043-50.
    • (2012) Am J Gastroenterol , vol.107 , pp. 1043-1050
    • Agrawal, A.1    Sharma, B.C.2    Sharma, P.3    Sarin, S.K.4
  • 44
    • 33947392621 scopus 로고    scopus 로고
    • Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy
    • DOI 10.1002/hep.21533
    • Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007;45:549-59. (Pubitemid 46450607)
    • (2007) Hepatology , vol.45 , Issue.3 , pp. 549-559
    • Prasad, S.1    Dhiman, R.K.2    Duseja, A.3    Chawla, Y.K.4    Sharma, A.5    Agarwal, R.6
  • 45
    • 79951678831 scopus 로고    scopus 로고
    • Meta-analysis: The effects of gut flora modulation using prebiotics, probiotics and synbiotics on minimal hepatic encephalopathy
    • Shukla S, Shukla A, Mehboob S, Guha S. Meta-analysis: the effects of gut flora modulation using prebiotics, probiotics and synbiotics on minimal hepatic encephalopathy. Aliment Pharmacol Ther 2011;33:662-71.
    • (2011) Aliment Pharmacol Ther , vol.33 , pp. 662-671
    • Shukla, S.1    Shukla, A.2    Mehboob, S.3    Guha, S.4
  • 46
    • 80955157383 scopus 로고    scopus 로고
    • Clinical efficacy and safety of lactulose for minimal hepatic encephalopathy: A meta-analysis
    • Luo M, Li L, Lu CZ, Cao WK. Clinical efficacy and safety of lactulose for minimal hepatic encephalopathy: a meta-analysis. Eur J Gastroenterol Hepatol 2011;23:1250-7.
    • (2011) Eur J Gastroenterol Hepatol , vol.23 , pp. 1250-1257
    • Luo, M.1    Li, L.2    Lu, C.Z.3    Cao, W.K.4
  • 48
    • 0023552427 scopus 로고
    • Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: A double-blind, randomized trial
    • DOI 10.1002/hep.1840070617
    • Morgan MY, Hawley KE. Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double-blind, randomized trial. Hepatology 1987;7:1278-84. (Pubitemid 18014202)
    • (1987) Hepatology , vol.7 , Issue.6 , pp. 1278-1284
    • Morgan, M.Y.1    Hawley, K.E.2
  • 49
    • 0023772137 scopus 로고
    • Lactitol vs. Lactulose in the treatment of chronic recurrent portalsystemic encephalopathy
    • Heredia D, Teres J, Orteu N, Rodes J. Lactitol vs. lactulose in the treatment of chronic recurrent portalsystemic encephalopathy. J Hepatol 1988;7:106-10.
    • (1988) J Hepatol , vol.7 , pp. 106-110
    • Heredia, D.1    Teres, J.2    Orteu, N.3    Rodes, J.4
  • 50
    • 84862664992 scopus 로고    scopus 로고
    • Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites
    • Kalambokis GN, Mouzaki A, Rodi M, Pappas K, Fotopoulos A, Xourgia X et al. Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites. Clin Gastroenterol Hepatol 2012;10:815-8.
    • (2012) Clin Gastroenterol Hepatol , vol.10 , pp. 815-818
    • Kalambokis, G.N.1    Mouzaki, A.2    Rodi, M.3    Pappas, K.4    Fotopoulos, A.5    Xourgia, X.6
  • 52
    • 85044701545 scopus 로고
    • Neomycin in the treatment of hepatic coma
    • 21
    • Dawson AM, Mc LJ, Sherlock S. Neomycin in the treatment of hepatic coma. Lancet 1957 21;273:1262-8.
    • (1957) Lancet , vol.273 , pp. 1262-1268
    • Dawson, A.M.1    Mc, L.J.2    Sherlock, S.3
  • 53
    • 0017744177 scopus 로고
    • Comparison of lactulose and neomycin in the treatment of chronic portal systemic encephalopathy. A double blind controlled trial
    • Conn HO, Leevy CM, Vlahcevic ZR, Rodgers JB, Maddrey WC, Seeff L et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology 1977;72(4 Pt 1):573-83. (Pubitemid 8097592)
    • (1977) Gastroenterology , vol.72 , Issue.41 , pp. 573-583
    • Conn, H.O.1    Leevy, C.M.2    Vlahcevic, Z.R.3
  • 54
    • 0030868006 scopus 로고    scopus 로고
    • Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial
    • Miglio F, Valpiani D, Rossellini SR, Ferrieri A. Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial. Curr Med Res Opin 1997;13:593-601. (Pubitemid 27404093)
    • (1997) Current Medical Research and Opinion , vol.13 , Issue.10 , pp. 593-601
    • Miglio, F.1    Valpiani, D.2    Rossellini, S.R.3    Ferrieri, A.4    Canova, N.5
  • 57
    • 18644365788 scopus 로고    scopus 로고
    • Rifaximin: In vitro and in vivo antibacterial activity - A review
    • DOI 10.1159/000081991
    • Jiang ZD, DuPont HL. Rifaximin: in vitro and in vivo antibacterial activity - a review. Chemotherapy 2005;51(Suppl 1):67-72. (Pubitemid 40663191)
    • (2005) Chemotherapy , vol.51 , Issue.SUPPL. 1 , pp. 67-72
    • Jiang, Z.D.1    Dupont, H.L.2
  • 58
    • 0035986441 scopus 로고    scopus 로고
    • Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis
    • Brigidi P, Swennen E, Rizzello F, Bozzolasco M, Matteuzzi D. Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis. J Chemother 2002;14:290-5. (Pubitemid 34734574)
    • (2002) Journal of Chemotherapy , vol.14 , Issue.3 , pp. 290-295
    • Brigidi, P.1    Swennen, E.2    Rizzello, F.3    Bozzolasco, M.4    Matteuzzi, D.5
  • 59
    • 79251535022 scopus 로고    scopus 로고
    • Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy
    • Bajaj JS, Heuman DM, Wade JB, Gibson DP, Saeian K, Wegelin JA et al. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 2011;140:478-87 e1.
    • (2011) Gastroenterology , vol.140
    • Bajaj, J.S.1    Heuman, D.M.2    Wade, J.B.3    Gibson, D.P.4    Saeian, K.5    Wegelin, J.A.6
  • 61
    • 84878018203 scopus 로고    scopus 로고
    • Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: What is the evidence?
    • Gluud LL, Dam G, Borre M, Les I, Cordoba J,chesini G et al. Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence? Metab Brain Dis 2013;28:221-5.
    • (2013) Metab Brain Dis , vol.28 , pp. 221-225
    • Gluud, L.L.1    Dam, G.2    Borre, M.3    Les, I.4    Cordoba, J.5    Chesini, G.6
  • 63
    • 79751499077 scopus 로고    scopus 로고
    • Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial)
    • Sidhu SS, Goyal O, Mishra BP, Sood A, Chhina RS, Soni RK. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). Am J Gastroenterol 2011;106:307-16.
    • (2011) Am J Gastroenterol , vol.106 , pp. 307-316
    • Sidhu, S.S.1    Goyal, O.2    Mishra, B.P.3    Sood, A.4    Chhina, R.S.5    Soni, R.K.6
  • 65
    • 55349090301 scopus 로고    scopus 로고
    • Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: A meta-analysis
    • Jiang Q, Jiang XH, Zheng MH, Jiang LM, Chen YP, Wang L. Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis. Eur J Gastroenterol Hepatol 2008;20:1064-70.
    • (2008) Eur J Gastroenterol Hepatol , vol.20 , pp. 1064-1070
    • Jiang, Q.1    Jiang, X.H.2    Zheng, M.H.3    Jiang, L.M.4    Chen, Y.P.5    Wang, L.6
  • 66
    • 84857577254 scopus 로고    scopus 로고
    • Rifaximin vs. Conventional oral therapy for hepatic encephalopathy: A meta-analysis
    • Eltawil KM, Laryea M, Peltekian K, Molinari M. Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis. World J Gastroenterol 2012;18:767-77.
    • (2012) World J Gastroenterol , vol.18 , pp. 767-777
    • Eltawil, K.M.1    Laryea, M.2    Peltekian, K.3    Molinari, M.4
  • 68
    • 84883744232 scopus 로고    scopus 로고
    • A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy
    • Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol 2013;108:1458-63.
    • (2013) Am J Gastroenterol , vol.108 , pp. 1458-1463
    • Sharma, B.C.1    Sharma, P.2    Lunia, M.K.3    Srivastava, S.4    Goyal, R.5    Sarin, S.K.6
  • 69
    • 0035150737 scopus 로고    scopus 로고
    • Probiotics, prebiotics, and synbiotics - Approaching a definition
    • Schrezenmeir J, de Vrese M. Probiotics, prebiotics, and synbiotics - approaching a definition. Am J Clin Nutr 2001;73(2 Suppl):361S-4S. (Pubitemid 32113256)
    • (2001) American Journal of Clinical Nutrition , vol.73 , Issue.2 SUPPL.
    • Schrezenmeir, J.1    De Vrese, M.2
  • 71
    • 2342580955 scopus 로고    scopus 로고
    • Synbiotic Modulation of Gut Flora: Effect on Minimal Hepatic Encephalopathy in Patients with Cirrhosis
    • DOI 10.1002/hep.20194
    • Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004;39:1441-9. (Pubitemid 38569067)
    • (2004) Hepatology , vol.39 , Issue.5 , pp. 1441-1449
    • Liu, Q.1    Duan, Z.P.2    Ha, D.K.3    Bengmark, S.4    Kurtovic, J.5    Riordan, S.M.6
  • 72
    • 34848832109 scopus 로고    scopus 로고
    • Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: A randomized, double-blind, placebo-controlled study
    • DOI 10.1007/s10620-006-9687-y
    • Malaguarnera M, Greco F, Barone G, Gargante MP, Malaguarnera M, Toscano MA. Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Dig Dis Sci 2007;52:3259-65. (Pubitemid 47512537)
    • (2007) Digestive Diseases and Sciences , vol.52 , Issue.11 , pp. 3259-3265
    • Malaguarnera, M.1    Greco, F.2    Barone, G.3    Gargante, M.P.4    Malaguarnera, M.5    Toscano, M.A.6
  • 73
    • 84865420970 scopus 로고    scopus 로고
    • Systematic review and meta-analysis of randomized trials on probiotics for hepatic encephalopathy
    • Holte K, Krag A, Gluud LL. Systematic review and meta-analysis of randomized trials on probiotics for hepatic encephalopathy. Hepatol Res 2012;42:1008-15.
    • (2012) Hepatol Res , vol.42 , pp. 1008-1015
    • Holte, K.1    Krag, A.2    Gluud, L.L.3
  • 75
    • 80155209767 scopus 로고    scopus 로고
    • A randomized double blind placebo controlled trial of probiotics in minimal hepatic encephalopathy
    • Saji S, Kumar S, Thomas V. A randomized double blind placebo controlled trial of probiotics in minimal hepatic encephalopathy. Trop Gastroenterol 2011;32:128-32.
    • (2011) Trop Gastroenterol , vol.32 , pp. 128-132
    • Saji, S.1    Kumar, S.2    Thomas, V.3
  • 76
    • 0025231570 scopus 로고
    • Nitrogen metabolism in liver: Structural and functional organization and physiological relevance
    • 15
    • Haussinger D. Nitrogen metabolism in liver: structural and functional organization and physiological relevance. Biochem J 1990 15;267:281-90
    • (1990) Biochem J , vol.267 , pp. 281-290
    • Haussinger, D.1
  • 78
    • 84856048480 scopus 로고    scopus 로고
    • Efficacy of L-omithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy
    • Abid S, Jafri W, Mumtaz K, Islam M, Abbas Z, Shah HA et al. Efficacy of L-omithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy. J Coll Physicians Surg Pak 2011;21:666-71.
    • (2011) J Coll Physicians Surg Pak , vol.21 , pp. 666-671
    • Abid, S.1    Jafri, W.2    Mumtaz, K.3    Islam, M.4    Abbas, Z.5    Shah, H.A.6
  • 79
    • 84876982943 scopus 로고    scopus 로고
    • 1-ornithine-1-aspartate for hepatic encephalopathy in patients with cirrhosis: A meta-analysis of randomized controlled trials
    • Bai M, Yang Z, Qi X, Fan D, Han G. 1-ornithine-1-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2013;28:783-92.
    • (2013) J Gastroenterol Hepatol , vol.28 , pp. 783-792
    • Bai, M.1    Yang, Z.2    Qi, X.3    Fan, D.4    Han, G.5
  • 80
    • 79959499072 scopus 로고    scopus 로고
    • The effect of L-ornithine L-aspartate and branch chain amino acids on encephalopathy and nutritional status in liver cirrhosis with malnutrition
    • Ndraha S, Hasan I, Simadibrata M. The effect of L-ornithine L-aspartate and branch chain amino acids on encephalopathy and nutritional status in liver cirrhosis with malnutrition. Acta Med Indones 2011;43:18-22.
    • (2011) Acta Med Indones , vol.43 , pp. 18-22
    • Ndraha, S.1    Hasan, I.2    Simadibrata, M.3
  • 81
    • 84907877160 scopus 로고    scopus 로고
    • Oral 1-ornithine-1-aspartate in minimal hepatic encephalopathy: A randomized, double blind placebo-controlled trial
    • Epub ahead of print
    • Alvares-da-Silva MR, de Araujo A, Vicenzi JR, da Silva GV, Oliveira FB, Schacher F et al. Oral 1-ornithine-1-aspartate in minimal hepatic encephalopathy: a randomized, double blind placebo-controlled trial. Hepatol Res 2013 [Epub ahead of print].
    • (2013) Hepatol Res
    • Alvares-da-Silva, M.R.1    De Araujo, A.2    Vicenzi, J.R.3    Da Silva, G.V.4    Oliveira, F.B.5    Schacher, F.6
  • 82
    • 77950614259 scopus 로고    scopus 로고
    • A double-blind, randomized, placebo-controlled trial of intravenous L-omithine-L-aspartate on postural control in patients with cirrhosis
    • Schmid M, Peck-Radosavljevic M, Konig F, Mittermaier C, Gangl A, Ferenci P. A double-blind, randomized, placebo-controlled trial of intravenous L-omithine-L-aspartate on postural control in patients with cirrhosis. Liver Int 2010;30:574-82.
    • (2010) Liver Int , vol.30 , pp. 574-582
    • Schmid, M.1    Peck-Radosavljevic, M.2    Konig, F.3    Mittermaier, C.4    Gangl, A.5    Ferenci, P.6
  • 83
    • 0015218210 scopus 로고
    • False neurotransmitters and hepatic failure
    • 10
    • Fischer JE, Baldessarini RJ. False neurotransmitters and hepatic failure. Lancet 1971 10;2:75-80.
    • (1971) Lancet , vol.2 , pp. 75-80
    • Fischer, J.E.1    Baldessarini, R.J.2
  • 84
    • 79951683404 scopus 로고    scopus 로고
    • Diet and cognition in chronic liver disease
    • Kachaamy T, Bajaj JS. Diet and cognition in chronic liver disease. Curr Opin Gastroenterol 2011;27:174-9.
    • (2011) Curr Opin Gastroenterol , vol.27 , pp. 174-179
    • Kachaamy, T.1    Bajaj, J.S.2
  • 85
    • 84881361645 scopus 로고    scopus 로고
    • Oral branched-chain amino acids have a beneficial effect on manifestations of hepatic encephalopathy in a systematic review with meta-analyses of randomized controlled trials
    • Gluud LL, Dam G, Borre M, Les I, Cordoba J,chesini G et al. Oral branched-chain amino acids have a beneficial effect on manifestations of hepatic encephalopathy in a systematic review with meta-analyses of randomized controlled trials. J Nutr 2013;143:1263-8.
    • (2013) J Nutr , vol.143 , pp. 1263-1268
    • Gluud, L.L.1    Dam, G.2    Borre, M.3    Les, I.4    Cordoba, J.5    Chesini, G.6
  • 88
    • 0026661330 scopus 로고
    • Sodium benzoate in the treatment of acute hepatic encephalopathy: A double-blind randomized trial
    • Sushma S, Dasarathy S, Tandon RK, Jain S, Gupta S, Bhist MS. Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial. Hepatology 1992;16:138-44.
    • (1992) Hepatology , vol.16 , pp. 138-144
    • Sushma, S.1    Dasarathy, S.2    Tandon, R.K.3    Jain, S.4    Gupta, S.5    Bhist, M.S.6
  • 89
    • 0035225784 scopus 로고    scopus 로고
    • Benzodiazepine receptor antagonists for acute and chronic hepatic encephalopathy
    • Als-Nielsen B, Kjaergard LL, Gluud C. Benzodiazepine receptor antagonists for acute and chronic hepatic encephalopathy. Cochrane Database Syst Rev 2001:CD002798.
    • (2001) Cochrane Database Syst Rev
    • Als-Nielsen, B.1    Kjaergard, L.L.2    Gluud, C.3
  • 90
    • 0025768460 scopus 로고
    • Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy. Results of a double-blind crossover trial
    • Riggio O, Ariosto F, Merli M, Caschera M, Zullo A, Balducci G et al. Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy. Results of a double-blind crossover trial. Dig Dis Sci 1991;36:1204-8.
    • (1991) Dig Dis Sci , vol.36 , pp. 1204-1208
    • Riggio, O.1    Ariosto, F.2    Merli, M.3    Caschera, M.4    Zullo, A.5    Balducci, G.6
  • 91
    • 67949085071 scopus 로고    scopus 로고
    • Prognosis and 1-year mortality of intensive care unit patients with severe hepatic encephalopathy
    • Fichet J, Mercier E, Genee O, Garot D, Legras A, Dequin PF et al. Prognosis and 1-year mortality of intensive care unit patients with severe hepatic encephalopathy. J Crit Care 2009;24:364-70.
    • (2009) J Crit Care , vol.24 , pp. 364-370
    • Fichet, J.1    Mercier, E.2    Genee, O.3    Garot, D.4    Legras, A.5    Dequin, P.F.6
  • 92
    • 78649663017 scopus 로고    scopus 로고
    • Incomplete Reversal of Cognitive Dysfunction After Liver Transplantation in Individuals Who Had Overt Hepatic Encephalopathy Before Liver Transplantation
    • Campagna F BA, Montagnese S et al. Incomplete Reversal of Cognitive Dysfunction After Liver Transplantation in Individuals Who Had Overt Hepatic Encephalopathy Before Liver Transplantation. J Hepatol 2010 (52 [Suppl]):S187.
    • (2010) J Hepatol , Issue.52 SUPPL.
    • Campagna, F.1    B, A.2    Montagnese, S.3
  • 94
    • 61549097213 scopus 로고    scopus 로고
    • Management options for minimal hepatic encephalopathy
    • Bajaj JS. Management options for minimal hepatic encephalopathy. Expert Rev Gastroenterol Hepatol 2008;2:785-90.
    • (2008) Expert Rev Gastroenterol Hepatol , vol.2 , pp. 785-790
    • Bajaj, J.S.1
  • 96
    • 75749105423 scopus 로고    scopus 로고
    • Review article: The modern management of hepatic encephalopathy
    • Bajaj JS. Review article: the modern management of hepatic encephalopathy. Aliment Pharmacol Ther 2010;31:537-47.
    • (2010) Aliment Pharmacol Ther , vol.31 , pp. 537-547
    • Bajaj, J.S.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.